Effectiveness of Switch to Erythropoiesis-Stimulating Agent (ESA) Biosimilars versus Maintenance of ESA Originators in the Real-Life Setting: Matched-Control Study in Hemodialysis Patients.

Roberto Minutolo,Piergiorgio Bolasco,Paolo Chiodini,Stefano Sposini,Maurizio Borzumati,Cataldo Abaterusso,Alessandra Antonia Mele,Domenico Santoro,Valeria Canale,Alberto Santoboni,Oliviero Filiberti,Fulvio Fiorini,Carlo Mura,Patrizio Imperiali,Silvio Borrelli,Luigi Russo,Luca De Nicola,Domenico Russo

Effectiveness of Switch to Erythropoiesis-Stimulating Agent (ESA) Biosimilars versus Maintenance of ESA Originators in the Real-Life Setting: Matched-Control Study in Hemodialysis Patients.

2017

Roberto Minutolo
Piergiorgio Bolasco
Paolo Chiodini
Stefano Sposini
Maurizio Borzumati
Cataldo Abaterusso
Alessandra Antonia Mele
Domenico Santoro
Valeria Canale
Alberto Santoboni
Oliviero Filiberti
Fulvio Fiorini
Carlo Mura
Patrizio Imperiali
Silvio Borrelli
Luigi Russo
Luca De Nicola
Domenico Russo

Background In hemodialysis (HD), switching from erythropoiesis-stimulating agent (ESA) originators to biosimilars is associated with the need for doses approximately 10% higher, according to industry-driven studies.

Keywords:

Biosimilar Pharmaceuticals
Diabetes mellitus
Biosimilar
Anesthesia
Intensive care medicine
Pharmacology
Anemia
Medicine
Retrospective cohort study
Erythropoiesis-stimulating agent
Hemodialysis
Internal medicine
Propensity score matching
Confidence interval
Clinical endpoint

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations